In agreement with this speculation, the pharmacological depletion of LDs by DGAT1 and DGAT2 inhibitor treatment significantly slows down cell growth and proliferation of lung cancer cells, especially those with higher LD contents, such as A549 and H460 (Figure 5). Here, DGAT2 is linked to lung cancer.